SEC Form 4 · accession 0001701247-26-000011
Enliven Therapeutics, Inc. · ELVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Louise Collins
Officer — CHIEF MEDICAL OFFICER
Period of report
Jul 17, 2026
Accepted (ET)
Jul 21, 2026 · 5:23 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001672619
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 17, 2026 | M | 5,000 | $2.48 | A | 30,000 | D | |
| Common StockF3,F2 | Jul 17, 2026 | S | 231 | $50.0542 | D | 29,769 | D | |
| Common StockF4,F2 | Jul 17, 2026 | S | 459 | $51.5466 | D | 29,310 | D | |
| Common StockF5,F2 | Jul 17, 2026 | S | 2,063 | $52.3921 | D | 27,247 | D | |
| Common StockF6,F2 | Jul 17, 2026 | S | 2,184 | $53.4199 | D | 25,063 | D | |
| Common StockF7,F8 | Jul 17, 2026 | S | 63 | $53.9208 | D | 25,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F9 | $2.48 | Jul 17, 2026 | M | 5,000 | D | — | Jun 17, 2031 | Common Stock | 5,000 | 116,268 | D |
Explanation of responses
- F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3565. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4This transaction was executed in multiple trades at prices ranging from $50.85 to $51.8305. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5This transaction was executed in multiple trades at prices ranging from $51.8711 to $52.845. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6This transaction was executed in multiple trades at prices ranging from $52.8741 to $53.8708. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F7This transaction was executed in multiple trades at prices ranging from $53.8793 to $53.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F8These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F9All of the shares subject to this option are fully vested and exercisable as of the date hereof.